Table 6. Serum levels of IGF-I, IGFBP-1, IGFBP-3, insulin, and risk of endometrial cancer, according to use of HRT (ever or never used during lifetime).
|
Quartiles (among controls) |
|||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| Age-adjusted and multivariate models** | OR (95 CI%) | OR (95 CI%) | OR (95 CI%) | OR (95 CI%) | P trend |
| IGF-I (P interaction IGF1/HRT=0.22) | |||||
| HRT ever users | |||||
| Cases/controls | 39/13 | 28/30 | 29/27 | 49/40 | |
| Model A | 1.0 | 0.32 (0.014–0.72) | 0.39 (0.17–0.89) | 0.45 (0.21–0.97) | 0.18 |
| Model B | 1.0 | 0.24 (0.09–0.64) | 0.36 (0.13–0.96) | 0.38 (0.16–0.92) | 0.17 |
| Model C | 1.0 | 0.46 (0.14–1.48) | 0.62 (0.19–2.03) | 0.43 (0.15–1.23) | 0.19 |
| HRT never users | |||||
| Cases/controls | 45/65 | 23/48 | 34/50 | 27/40 | |
| Age (years) | 1.0 | 0.73 (0.39–1.36) | 1.08 (0.60–1.95) | 1.08 (0.57–2.03) | 0.65 |
| Age, BMI, DM, PA | 1.0 | 0.54 (0.24–1.18) | 0.78 (0.36–1.67) | 1.22 (0.55–2.69) | 0.66 |
| Age, BMI, DM, PA, MP, OC | 1.0 | 0.59 (0.26–1.32) | 0.98 (0.44–2.20) | 1.44 (0.62–3.31) | 0.38 |
| IGFBP-1 (P interaction BP1/HRT=0.02) | |||||
| HRT ever users | |||||
| Cases/controls | 31/43 | 30/31 | 40/19 | 44/17 | |
| Model A | 1.0 | 1.30 (0.66–2.58) | 2.69 (1.29–5.60) | 3.29 (1.56–6.93) | <0.0001 |
| Model B | 1.0 | 1.50 (0.64–3.51) | 3.76 (1.52–9.30) | 4.12 (1.60–10.61) | 0.001 |
| Model C | 1.0 | 1.58 (0.56–4.44) | 6.24 (1.80–21.66) | 3.84 (1.10–13.42) | 0.012 |
| HRT never users | |||||
| Cases/controls | 26/37 | 23/45 | 37/59 | 43/62 | |
| Model A | 1.0 | 0.72 (0.35–1.47) | 0.86 (0.44–1.64) | 0.94 (0.49–1.78) | 0.94 |
| Model B | 1.0 | 0.85 (0.35–2.03) | 0.82 (0.37–1.81) | 0.94 (0.40–2.19) | 0.89 |
| Model D | 1.0 | 0.65 (0.25–1.72) | 0.53 (0.22–1.27) | 0.54 (0.21–1.38) | 0.19 |
| IGFBP-3 (P interaction BP3/HRT=0.09) | |||||
| HRT ever users | |||||
| Cases/controls | 33/15 | 41/27 | 28/29 | 35/38 | |
| Model A | 1.0 | 0.66 (0.30–1.45) | 0.43 (0.19–0.96) | 0.43 (0.20–0.92) | 0.02 |
| Model B | 1.0 | 0.85 (0.33–2.20) | 0.49 (0.18–1.30) | 0.55 (0.22–1.38) | 0.12 |
| Model C | 1.0 | 0.97 (0.29–3.24) | 0.56 (0.17–1.88) | 0.91 (0.29–2.94) | 0.73 |
| HRT never users | |||||
| Cases/controls | 33/51 | 31/49 | 28/45 | 28/32 | |
| Model A | 1.0 | 0.97 (0.52–1.83) | 0.97 (0.51–1.86) | 1.33 (0.68–2.61) | 0.46 |
| Model B | 1.0 | 0.86 (0.40–1.88) | 0.78 (0.34–1.78) | 1.54 (0.68–3.52) | 0.42 |
| Model D | 1.0 | 0.68 (0.30–1.56) | 0.86 (0.36–2.07) | 1.53 (0.64–3.64) | 0.32 |
| Insulin (P interaction ins/HRT=0.000) | |||||
| HRT ever users | |||||
| Cases/controls | 29/13 | 44/25 | 38/20 | 29/51 | |
| Model A | 1.0 | 0.75 (0.33–1.71) | 0.82 (0.35–1.93) | 0.24 (0.11–0.54) | <0.0001 |
| Model B | 1.0 | 0.72 (0.26–1.97) | 0.55 (0.18–1.66) | 0.13 (0.04–0.40) | <0.0001 |
| Model C | 1.0 | 0.72 (0.18–2.83) | 0.44 (0.07–1.98) | 0.11 (0.03–0.49) | <0.0001 |
| HRT never users | |||||
| Cases/controls | 15/43 | 39/62 | 29/56 | 37/26 | |
| Model A | 1.0 | 1.79 (0.88–3.65) | 1.47 (0.70–3.08) | 3.97 (1.82–8.66) | 0.002 |
| Model B | 1.0 | 1.52 (0.65–3.56) | 0.88 (0.34–2.30) | 2.18 (0.81–5.84) | 0.29 |
| Model D | 1.0 | 1.60 (0.64–3.98) | 1.07 (0.38–3.03) | 2.44 (0.85–7.07) | 0.18 |
HRT=hormone replacement therapy; OC=oral contraceptives.
**
The multivariate models include indicators for: Model (A) age. Model (B) age, body mass index (BMI), diabetes mellitus, and physical activity. Model (C) same as Model (B) adding menopausal status, types of HRT used (unopposed oestrogens, cyclic combined, continuous combined), and use of OCs. Model (D) same as Model (C) with or without HRT.